---
verdict: MATERIAL-GAPS-FIX-AND-RESWEEP
pass: dr_output_pass_5_tirzepatide_v6
commit: f7914da
delta_vs_pass2: "Not closed. The audited V8 artifact is worse than the supplied target summary: manifest status is abort_evaluator_critical, release_allowed=false, bibliography has 16 citations rather than 19, T1+T2 is 56.25% rather than 94.7%, Lilly review PMC10115620 and PRNewswire remain cited, and Qwen flags citation tightness as needs_revision."
citations_verified: 16/16
t1_t2_percentage_of_bibliography: "56.25%"
t7_percentage_of_bibliography: "12.50%"
faithfulness_verdict: "Fails top-tier DR. Most prose sentences are plausibly supported by adjacent citations, but key efficacy claims rely on a review plus PRNewswire rather than primary SURPASS papers, several numeric/methods/contradiction claims lack tight citation support, and Qwen independently flagged citation-source mismatch for SURPASS-3/SURPASS-5."
coverage_gaps_remaining: ["SURPASS-1 primary not cited", "SURPASS-3 primary not cited", "SURPASS-4 primary not cited", "SURPASS-5 primary not cited despite claim use", "SURPASS-6 not cited", "SURPASS-AP-Combo not cited", "SELECT absent", "LEADER absent", "SUSTAIN absent", "REWIND absent", "PIONEER absent", "STEP appears only as comparator context"]
structural_hallucinations: ["Report bibliography has 16 citations, not the expected 19", "Manifest reports abort_evaluator_critical while pass context describes partial_qwen_advisory", "Safety section imports obesity-without-diabetes SURMOUNT-3/SURMOUNT-5 evidence into a T2DM question without using it only as clearly secondary external safety context", "Contradiction disclosures list mechanically extracted numeric conflicts without study/population/unit adjudication"]
quantification_quality: "Plain-English quantification is present for HbA1c, weight, adverse events, and cardiovascular noninferiority, but quality is undermined by weak source anchoring, uncited contradiction numerics, unit/population mixing, and missing primary trial citations."
contradiction_handling: "Mechanical disclosure only. The report lists 12 numeric contradiction clusters but does not adjudicate by population, endpoint, unit, dose, time point, trial design, or source tier; several contradictions appear to be extraction artifacts rather than true clinical conflicts."
vs_gpt54_dr_verdict: "Below GPT-5.4 Deep Research quality; not releasable."
vs_gemini31_pro_dr_verdict: "Below Gemini 3.1 Pro Deep Research quality; not releasable."
rationale: |
  The user mandated a line-by-line audit rather than pattern matching. I read manifest.json, bibliography.json, report.md cover to cover, qwen_judge_output.json, verification_details.json, evaluator_rule_checks.json, contradictions.json, and compared V8 directly with V5 for the named failure modes.

  The audited V8 output cannot be accepted as top-tier DR. It is internally gated as abort_evaluator_critical with release_allowed=false. The bibliography still cites the Lilly review PMC10115620 and PRNewswire, does not cite the primary SURPASS trial papers needed for the central claims, includes T4/T5/T6/T7 sources in high-value claim positions, and only reaches 56.25% T1+T2. Qwen specifically flags citation tightness and SURPASS-3/SURPASS-5 citation mismatch. The report is concise and readable, but it is not evidence-disciplined at the level required.
---

**Verdict**

MATERIAL-GAPS-FIX-AND-RESWEEP.

The V8 artifact under `outputs/full_scale_v8/clinical/clinical_tirzepatide_t2dm/` does not meet top-tier Deep Research quality. It is not a borderline pass: the manifest itself blocks release (`status=abort_evaluator_critical`, `release_allowed=false`) and identifies `citation_tightness` plus uncited numeric claims as critical issues.

The supplied context says V6 had 19 citations, 94.7% T1+T2, 0% T7, no T6/T7 bibliography citations, and `partial_qwen_advisory`. The actual audited V8 files have 16 citations, 56.25% T1+T2, 6.25% T6, 12.50% T7, and `abort_evaluator_critical`. I judged the files on disk, not the expected summary.

**Quantitative V6 vs V5 Summary**

Audited V5:
- Status: `partial_qwen_advisory`; release_allowed=false.
- Bibliography: 27 total citations.
- T1=6, T2=11, T6=2, T7=6, UNKNOWN=2.
- T1+T2: 17/27 = 62.96%.
- T6+T7: 8/27 = 29.63%.
- Generator: 1154 words; 40 verified sentences.

Audited V8:
- Status: `abort_evaluator_critical`; release_allowed=false.
- Evaluator gate: `abort`; reasons include `rule_pt11_uncited_numeric_claims`, `advisory_pt13_unhedged_superlatives`, and `qwen_citation_tightness_needs_revision`.
- Bibliography: 16 total citations, not 19.
- T1=6, T2=3, T4=3, T5=1, T6=1, T7=2.
- T1+T2: 9/16 = 56.25%.
- T6+T7: 3/16 = 18.75%.
- Generator: 621 words; 19 verified sentences; 8 dropped sentences.

Directionally, V8 reduced T6/T7 count versus V5, but it also reduced primary/systematic-review dominance, kept the exact disallowed Lilly review/PRNewswire pattern, and worsened the evaluator gate from partial advisory to abort.

**Criterion-by-criterion**

a. Faithfulness:

Fails top-tier DR. I checked the report line by line and cross-checked against bibliography, verification details, and Qwen. The 19 kept prose sentences are mostly adjacent-cited, but several core claims are not tightly anchored to the best available evidence. SURPASS-3 and SURPASS-5 numerical claims cite the Lilly review [1] and PRNewswire [2] rather than the primary SURPASS-3/SURPASS-5 RCT papers that are present in the corpus. The methods and contradiction sections contain many numeric assertions without proper citation markers, causing PT11 failure.

b. Evidence quality:

Fails. The bibliography visible to the reader is not primary-paper-heavy enough for this question. It includes:
- [1] Lilly review PMC10115620 marked T1, still used as the main SURPASS program anchor.
- [2] PRNewswire T6, still used for central SURPASS-3/SURPASS-5 numeric claims.
- [6] Lilly investor release T5 for SURMOUNT-3 safety and discontinuation.
- [7] Drug Topics T4 for SURMOUNT-5 discontinuation.
- [9] Mobile IV Medics T4 for prescribing-warning content.
- [10] and [11] T7 abstracts/posters for SURPASS-2 comparative claims.

This is not acceptable when primary RCTs and official labels are available in the corpus.

c. Coverage:

Fails. Required programs and comparators are not adequately covered.

Present in report/bibliography:
- SURPASS-2: present, but cited through T7 abstract/post-hoc sources rather than the primary trial paper.
- SURPASS-3: present in report, but not primary-cited.
- SURPASS-5: present in report, but not primary-cited.
- SURMOUNT: present, including obesity-without-diabetes SURMOUNT-3/SURMOUNT-5 content.
- STEP: present only as STEP 2 comparator context in an indirect comparison.

Absent or materially inadequate:
- SURPASS-1 primary: absent from report/bibliography.
- SURPASS-4 primary: absent.
- SURPASS-6: absent from V8 bibliography/report, despite present in V5 and corpus.
- SURPASS-AP-Combo: absent from final report/bibliography after dropped safety sentences.
- SELECT, LEADER, SUSTAIN, REWIND, PIONEER: absent.

d. Scope:

Partially improved but still not DR-grade. The V5 type 1 diabetes leakage is gone from the final V8 report, which is a real improvement. However, V8 still uses obesity-without-diabetes SURMOUNT-3 and SURMOUNT-5 safety evidence inside a T2DM report. It says those populations were without diabetes, but then uses them as ordinary safety evidence rather than clearly secondary, indirect, external-population context. The clinical question is adults with T2DM; T2DM safety should be anchored in SURPASS and label evidence first.

e. Argumentation:

Directionally readable, but not integrated at top-tier DR level. The report is mostly a sequence of individual study findings:
- Efficacy: SURPASS program summary, selected SURPASS-3/5 numbers, indirect semaglutide comparison, real-world study.
- Safety: GI events from review/obesity trials, meta-analysis, prescribing warning.
- Comparative: semaglutide/insulin/network meta-analysis/CVOT/model simulation.

It does not synthesize why estimates differ across dose, time point, population, background therapy, or comparator. It does not distinguish pivotal evidence from indirect/post-hoc/model-based evidence strongly enough.

f. Contradictions:

Fails. The contradiction disclosures remain mechanical. They list extracted numeric conflicts such as body weight values spanning negative percentages, HbA1c values misclassified as body-weight percentages, confidence-interval percentages misread as outcomes, and cross-population/cross-dose values mixed together. The report does not adjudicate by endpoint, unit, study design, population, dose, time point, or source tier.

Example: "tirzepatide / body weight (15 mg): values [2.37, 6.5, 7.0, 16.5, 48.4] %" mixes HbA1c-like values, threshold proportions, and body-weight outcomes. A top-tier DR report would explain which values are true contradictions and which are extraction artifacts.

g. Structural hallucinations:

Fails due to artifact/report inconsistencies and section-content mismatch:
- Bibliography has 16 citations, not 19 as expected.
- Manifest status is abort, not advisory.
- Methods says completeness checklist is 7/7, but the report misses major named programs requested for audit.
- Safety section scope drifts into obesity-only trials.
- Contradiction section is formatted as if it is clinically meaningful, but the clusters are not adjudicated.

The headings themselves are not invented; Efficacy, Safety, Comparative, Limitations, Methods, Contradiction disclosures, Bibliography are legitimate. The structural problem is that the content under them does not meet DR-grade evidence discipline.

h. Plain-English quantification:

Mixed. The report gives reader-friendly numbers for HbA1c, weight, discontinuation, GI adverse events, and noninferiority. But plain-English quantification is only valuable if it is tightly sourced and scoped. Here, key numbers are anchored to weak or mismatched sources, and contradiction numerics are dumped without interpretation.

**Citation-Level Audit Sample (20 citations)**

The bibliography contains only 16 citations, so I audited all 16 bibliography entries plus 4 report-level citation/claim failures.

1. [1] T1, PMC10115620 Lilly review. Still cited. Not an acceptable primary anchor for the SURPASS program when primary trial papers are in corpus.
2. [2] T6, PRNewswire. Still cited. Used for SURPASS-3/SURPASS-5 numeric efficacy claims; this directly fails the pass-2 gap.
3. [3] T1, indirect comparison vs semaglutide 2 mg. Acceptable for indirect comparative claims only; not a substitute for SURPASS-2 primary evidence.
4. [4] T1, real-world evaluation. Acceptable if framed observationally; report does hedge as "associated with."
5. [5] T4, MDPI review. Weak source for broad safety statement; should be replaced or supported by primary RCTs/label.
6. [6] T5, Lilly investor release. Weak and sponsor-controlled; used for SURMOUNT-3 safety/discontinuation in obesity without diabetes.
7. [7] T4, Drug Topics. Weak source; used for SURMOUNT-5 discontinuation rather than a primary trial publication or label.
8. [8] T2, network meta-analysis. Acceptable for comparative safety if limitations of indirect comparison are stated.
9. [9] T4, Mobile IV Medics safety page. Not acceptable for prescribing warning; should cite FDA label/official prescribing information.
10. [10] T7, SURPASS-2 abstract. Weak; should cite the primary SURPASS-2 RCT paper for direct head-to-head semaglutide comparison.
11. [11] T7, SURPASS-2 post-hoc abstract. Weak; acceptable only as secondary post-hoc context, not a core comparative anchor.
12. [12] T1, indirect comparison using SURMOUNT-2/STEP 2. Acceptable only for indirect T2DM overweight/obesity comparison; report states this.
13. [13] T2, systematic review vs insulin. Acceptable secondary synthesis, but should not replace primary SURPASS insulin-comparator trials.
14. [14] T2, network meta-analysis. Acceptable for ranking claims, but "most effective" should be tied to network assumptions and certainty.
15. [15] T1, SURPASS-CVOT NEJM. Strong source for cardiovascular noninferiority claim.
16. [16] T1, model-based simulation. Tier appears overgenerous for clinical effectiveness; report does hedge as simulation.
17. Report claim: SURPASS-3 HbA1c/body-weight values cite [1][2], not primary SURPASS-3 paper. Fails citation tightness.
18. Report claim: SURPASS-5 HbA1c/body-weight values cite [1][2], not primary SURPASS-5 RCT paper. Fails citation tightness.
19. Report limitation: "evidence base is heavily weighted toward lower-tier sources" is true for corpus but ambiguous for bibliography and uncited in prose. Needs clear corpus-vs-bibliography distinction.
20. Report contradiction list: 12 numeric contradiction clusters are uncited and not clinically adjudicated. Fails top-tier evidence interpretation.

**Did M-19 Prompt Changes Close the DR Pass 2 Gaps?**

No.

Gap 1, primary SURPASS papers in corpus but not cited:
Not closed. V8 still does not cite primary SURPASS-1/3/4/5/6/AP-Combo papers in the bibliography. SURPASS-3 and SURPASS-5 claims are supported by [1] review and [2] PRNewswire.

Gap 2, Lilly review plus PRNewswire:
Not closed. PMC10115620 is citation [1]. PRNewswire is citation [2].

Gap 3, scope leakage:
Partially closed. V5 type 1 diabetes content is removed from final report. Obesity-without-diabetes SURMOUNT-3/SURMOUNT-5 content remains in the Safety section and is not treated with enough caution for a T2DM-focused report.

Gap 4, contradiction handling mechanical:
Not closed. The contradiction section is still a raw numeric dump and includes likely extraction artifacts.

Gap 5, Qwen partial gate:
Worse. V5 was `partial_qwen_advisory`; V8 is `abort_evaluator_critical`. Qwen flags `citation_tightness` as `needs_revision` and specifically notes SURPASS-3/SURPASS-5 citation alignment problems.

**Remaining DR Gaps After M-19**

- Release gate is failed: `abort_evaluator_critical`, `release_allowed=false`.
- Actual V8 artifact does not match the expected pass summary: 16 citations, not 19; 56.25% T1+T2, not 94.7%.
- Primary pivotal trial papers are not the evidence backbone.
- Low-quality sources remain in high-value positions: PRNewswire, Lilly investor release, Drug Topics, Mobile IV Medics, abstracts.
- Safety evidence is not anchored first in T2DM trials and official label sources.
- Comparator landscape is incomplete: SELECT, LEADER, SUSTAIN, REWIND, PIONEER absent; STEP only appears indirectly.
- Contradiction handling is not clinically reasoned.
- Citation tightness fails both rule and Qwen checks.

**Required Fix**

1. Replace the bibliography/evidence selection for pivotal efficacy and safety with primary SURPASS papers: SURPASS-1, SURPASS-2, SURPASS-3, SURPASS-4, SURPASS-5, SURPASS-6, and SURPASS-AP-Combo where applicable.
2. Ban PRNewswire, investor releases, clinic pages, and trade press from final citations when primary papers, labels, or peer-reviewed systematic reviews exist.
3. Cite official prescribing information for boxed warning/contraindications instead of Mobile IV Medics or similar tertiary pages.
4. Rebuild safety around T2DM SURPASS safety data first; use SURMOUNT obesity-only trials only as explicitly indirect external-population context or omit them.
5. Add an adjudicated contradiction pass that normalizes endpoint, unit, population, comparator, dose, and time point; suppress extraction artifacts from the final contradiction section.
6. Add coverage checks for the named comparator programs: SELECT, LEADER, SUSTAIN, REWIND, PIONEER, STEP, with clear explanation when they are comparator/background rather than tirzepatide evidence.
7. Resweep and require manifest `release_allowed=true`, no PT11 blocker, Qwen citation_tightness at least `good`, and final bibliography at or above the intended T1+T2 threshold before judging again.
